BRISBANE, Calif., July 30 /EMWNews/ -- InterMune, Inc.

(Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, CEO and

President of InterMune, will present at the BMO Capital Markets 2008 Focus

on Healthcare Conference in New York on August 6, 2008 at 10:00 a.m. EDT.



    To access a live audio webcast of the presentation, investors and other

interested parties may log on to the investor relations page of InterMune's

corporate website at http://www.intermune.com. The company recommends

logging on to the site 15 minutes prior to the start of the presentation in

order to register or download any necessary software.

    About InterMune



    InterMune is a biotechnology company focused on the research,

development and commercialization of innovative therapies in pulmonology

and hepatology. InterMune has a research and development portfolio

addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV)

infections. The pulmonology portfolio includes the Phase 3 program,

CAPACITY, which is evaluating pirfenidone for the treatment of patients

with IPF and a research program focused on small molecules for pulmonary

disease. The hepatology portfolio includes the HCV protease inhibitor

compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a

second-generation HCV protease inhibitor research program, and a research

program evaluating a new target in hepatology. For additional information

about InterMune and its R&D pipeline, please visit

http://www.intermune.com.